Ownership and insider activity for Omeros Corporation (OMER): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion.
Price
| Price | $17.34 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-28 | Cancelmo Peter B | M-Exempt | 25,000 | $74K |
| 2026-08-31 | Cancelmo Peter B | M-Exempt | 25,000 | $74K |
| 2026-08-31 | Cancelmo Peter B | M-Exempt | 25,000 | $74K |
| 2026-08-31 | Cancelmo Peter B | S-Sale | 25,000 | $464K |
| 2026-08-28 | Cancelmo Peter B | S-Sale | 25,000 | $466K |
| 2026-08-27 | HANISH ARNOLD C | M-Exempt | 7,500 | $110K |
| 2026-08-26 | HANISH ARNOLD C | M-Exempt | 5,000 | $79K |
| 2026-08-27 | HANISH ARNOLD C | S-Sale | 5,000 | $94K |
| 2026-08-27 | HANISH ARNOLD C | M-Exempt | 2,500 | $40K |
| 2026-08-26 | HANISH ARNOLD C | M-Exempt | 5,000 | $79K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.2M | $3.4M | $5.9M | $3.1M | $10.5M | $100.8M | $11.0M | $7.1M | $3.4M | $9.7M |
| Short-term Investments | $43.1M | $80.4M | $54.6M | $57.7M | $124.5M | $56.5M | $183.9M | $164.7M | $86.7M | $162.1M |
| Receivables | $12.0M | $17.1M | $22.8M | $35.2M | $3.8M | $82.5M | $242.0M | $6.7M | $36.8M | $36.3M |
| Inventory | $1.1M | $443000 | $52.5M | $1.1M | $1.4M | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $60.3M | $108.4M | $89.9M | $103.7M | $151.3M | $248.0M | $443.2M | $217.9M | $134.1M | $215.7M |
| Property, Plant & Equipment | $1.2M | $2.1M | $3.8M | $30.9M | $28.1M | $30.0M | $23.3M | $20.6M | $17.6M | $12.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $67.3M | $116.3M | $95.9M | $137.0M | $181.0M | $419.3M | $591.0M | $378.3M | $277.1M | $325.6M |
| Accounts Payable | $2.5M | $6.7M | $6.3M | $5.3M | $4.2M | $13.4M | $6.0M | $7.7M | $5.9M | $4.8M |
| Short-term Debt | 0 | 0 | 0 | $3.5M | 0 | 0 | $94.4M | $8.6M | $21.0M | $17.1M |
| Total Current Liabilities | $16.1M | $26.3M | $37.4M | $55.5M | $36.7M | $51.8M | $136.4M | $53.3M | $79.5M | $78.1M |
| Long-term Debt | $79.5M | $83.3M | $149.0M | $158.2M | $236.3M | $313.5M | $220.9M | $329.7M | $166.6M | $208.5M |
| Total Liabilities | $104.7M | $119.1M | -$4.2M | $246.0M | $301.8M | $395.5M | $505.3M | $403.3M | $459.7M | $446.9M |
| Retained Earnings | -$469.9M | -$523.4M | $650.1M | -$734.6M | -$872.7M | -$683.1M | -$635.7M | -$753.5M | -$910.3M | -$913.7M |
| Total Equity | -$37.4M | -$2.8M | $650.1M | -$109.0M | -$120.8M | $23.8M | $85.7M | -$25.0M | -$182.6M | -$121.2M |
| Total Debt | $80.0M | $84.6M | $151.4M | $194.0M | $268.8M | $347.8M | $342.0M | $361.6M | $207.0M | $239.1M |
| Net Debt | $34.7M | $858000 | $91.0M | $133.2M | $133.9M | $190.6M | $147.1M | $189.7M | $116.9M | $67.3M |
| Working Capital | $44.2M | $82.1M | $52.5M | $48.3M | $114.5M | $196.2M | $306.9M | $164.6M | $54.6M | $137.6M |
Financial Health
| Debt / Equity | -1.63 |
| Current Ratio | 1.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.20 |
Profitability
| Return on Equity | -109.40% |
| Return on Invested Capital | -31.14% |
| Return on Assets | 43.52% |
| Gross Margin | 95.77% |
| Operating Margin | -189.53% |
| Net Margin | 324.88% |
Related companies: ADCT · BCYC · FDMT · FULC · GOSS · KALV · LXRX
Explore sector: Healthcare · Biotechnology
More sections of OMER: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks